No Data
Express News | Hubei Guangji Pharmaceutical: Signed a global strategic cooperation agreement
Express News | Hubei Guangji Pharmaceutical: The wholly-owned subsidiary Guanghua Pharmaceutical plans to increase capital and introduce strategic investors.
Guangji Pharmaceutical: Report for the third quarter of 2024
hubei guangji pharmaceutical (000952.SZ): a net loss of 0.159 billion yuan in the first three quarters.
Gelonghui October 30th | Hubei Guangji Pharmaceutical (000952.SZ) released the third quarter report for 2024, achieving revenue of 0.462 billion yuan in the first three quarters, a decrease of 11.54% year-on-year; net income attributable to shareholders of the listed company -0.159 billion yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses -0.172 billion yuan; basic earnings per share -0.4498 yuan.
Express News | This week, a total of 10 listed companies announced that the company or related parties were filed the next day after the announcement, Nuotai Biotechnology approached the 20% lower limit during the day.
Hubei Guangji Pharmaceutical was investigated by the CSRC for disclosure violations and was warned in November last year. | Quick read announcement
Tonight, hubei guangji pharmaceutical announced that it is under investigation by the China Securities Regulatory Commission for suspected violations of disclosure regulations; In May of this year, hubei guangji pharmaceutical experienced a wave of rising market trends; Currently, hubei guangji pharmaceutical is deeply trapped in poor performance.
No Data
No Data